| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | fim3 |
| Uniprot No | P17835 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 26-204aa |
| 氨基酸序列 | NDGTIVITGSISDQTCVIEEPSTLNHIKVVQLPKISKNALRNDGDTAGATPFDIKLKECPQALGALKLYFEPGITTNYDTGDLIAYKQTYNASGNGNLSTVSSATKAKGVEFRLANLNGQHIRMGTDKTTQAAQTFTGKVTNGSKSYTLRYLASYVKKPKEDVDAAQITSYVGFSVVYP |
| 预测分子量 | 21.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条关于Fim3重组蛋白的模拟参考文献示例(实际文献请通过学术数据库核实)：
---
1. **文献名称**: "Expression and purification of recombinant Fim3 protein from Bordetella pertussis in Escherichia coli"
**作者**: Smith A, et al.
**摘要**: 研究报道了在大肠杆菌系统中高效表达和纯化Fim3重组蛋白的方法，并通过SDS-PAGE和Western blot验证其抗原性，为后续疫苗开发提供基础。
2. **文献名称**: "Immunogenicity of Fim3-based subunit vaccine against pertussis"
**作者**: Li X, et al.
**摘要**: 评估了Fim3重组蛋白在小鼠模型中的免疫原性，发现其能诱导高滴度抗体并增强对百日咳杆菌的清除能力，支持其作为亚单位疫苗的潜力。
3. **文献名称**: "Structural and functional analysis of Fim3 adhesin in Bordetella pertussis biofilm formation"
**作者**: Garcia-Ramos E, et al.
**摘要**: 通过X射线晶体学解析Fim3蛋白结构，揭示其与宿主细胞结合的分子机制，并证明重组Fim3在细菌生物膜形成中的关键作用。
---
**注意**：以上为模拟内容，实际文献需通过PubMed、Web of Science等平台检索关键词“Fim3 recombinant protein”“Bordetella pertussis Fim3”获取。
**Background of Fim3 Recombinant Protein**
Fim3 is a key virulence factor expressed by *Bordetella pertussis*, the bacterium responsible for whooping cough. It is a subunit of fimbriae, filamentous surface proteins critical for bacterial adhesion to host respiratory tissues and biofilm formation. Among the several fimbrial serotypes (Fim2. Fim3. and FimX), Fim3 is epidemiologically significant due to its variable expression during infection and its association with disease resurgence in vaccinated populations.
Fim3 expression is regulated by the BvgAS two-component system, which activates virulence genes in response to environmental cues. Notably, Fim3 dominance fluctuates under selective pressures, such as vaccine-induced immunity. Acellular pertussis vaccines (aPVs), widely used today, often include Fim3 as a component alongside pertussis toxin and adhesins. However, incomplete or waning immunity has been linked to shifts in circulating *B. pertussis* strains, with Fim3-expressing variants becoming prevalent in some outbreaks.
Recombinant Fim3 protein is produced via genetic engineering, typically using *E. coli* or other expression systems, to study its immunogenicity, structural properties, and role in pathogenesis. It serves as a tool for developing improved vaccines, diagnostics, and therapeutics. Research on Fim3 also explores its potential as a standalone antigen or in combination with other virulence factors to enhance cross-protective immunity. Understanding Fim3’s molecular interactions and variability remains crucial for addressing vaccine evasion and controlling pertussis, particularly in vulnerable infant populations.
×
